Modern best practice in the management of benign prostatic hyperplasia in the elderly
- PMID: 32547642
- PMCID: PMC7273551
- DOI: 10.1177/1756287220929486
Modern best practice in the management of benign prostatic hyperplasia in the elderly
Abstract
Benign prostatic hyperplasia (BPH), with its associated lower urinary tract symptoms (LUTS), can be a debilitating disease in the elderly male. Transurethral resection of the prostate (TURP) remains the gold standard; however, many patients will choose to avoid surgery if possible. Medical therapy is an effective alternative, however, new studies are showing that there may be more side effects than previously realized in the elderly male. Newer, novel minimally invasive techniques, including UroLift® and Rezūm™, are gaining favor as alternative office-based procedural techniques that do not require general anesthesia and may better preserve ejaculatory function. Though promising, at this point, these techniques are not approved for all patients. With a range of medical, procedural, and surgical options for treatment of BPH with LUTS, it is important to have a discussion with your patient regarding the short- and long-term risks and benefits, as well as alternatives, before deciding on a treatment plan for your patient with BPH.
Keywords: ambulatory procedures; benign prostatic hyperplasia; elderly; medical therapy; surgery.
© The Author(s), 2020.
Conflict of interest statement
Conflict of interest statement: The authors declare that there is no conflict of interest.
Similar articles
-
Emerging, newly-approved treatments for lower urinary tract symptoms secondary to benign prostatic hypertrophy.Can J Urol. 2018 Apr;25(2):9228-9237. Can J Urol. 2018. PMID: 29679999 Review.
-
Recent developments in the surgical management of benign prostatic hyperplasia.Urology. 1998 Apr;51(4A Suppl):23-31. doi: 10.1016/s0090-4295(98)00052-1. Urology. 1998. PMID: 9586593 Review.
-
Office-Based Procedures for BPH.Curr Urol Rep. 2021 Dec 16;22(12):63. doi: 10.1007/s11934-021-01081-7. Curr Urol Rep. 2021. PMID: 34913101 Review.
-
Microwave thermotherapy for benign prostatic hyperplasia.Cochrane Database Syst Rev. 2007 Oct 17;(4):CD004135. doi: 10.1002/14651858.CD004135.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2012 Sep 12;(9):CD004135. doi: 10.1002/14651858.CD004135.pub3. PMID: 17943811 Updated. Review.
-
Management of Benign Prostatic Hyperplasia Larger than 100 ml: Simple Open Enucleation Versus Transurethral Laser Prostatectomy.Curr Urol Rep. 2016 Jun;17(6):44. doi: 10.1007/s11934-016-0601-7. Curr Urol Rep. 2016. PMID: 27048160 Review.
Cited by
-
Design and Evaluation of Inorganic/Organic Hybrid Bio-composite for Site-Specific Oral Delivery of Darifenacin.AAPS PharmSciTech. 2024 Sep 5;25(7):204. doi: 10.1208/s12249-024-02916-5. AAPS PharmSciTech. 2024. PMID: 39237789
-
Two-Year Outcomes of Prostatic Artery Embolization for Symptomatic Benign Prostatic Hyperplasia: An International, Multicenter, Prospective Study.Cardiovasc Intervent Radiol. 2024 Nov;47(11):1515-1524. doi: 10.1007/s00270-024-03802-0. Epub 2024 Sep 4. Cardiovasc Intervent Radiol. 2024. PMID: 39230672 Free PMC article.
-
A comparative study of histotripsy parameters for the treatment of fibrotic ex-vivo human benign prostatic hyperplasia tissue.Sci Rep. 2024 Sep 2;14(1):20365. doi: 10.1038/s41598-024-71163-2. Sci Rep. 2024. PMID: 39223181 Free PMC article.
-
A Comparative Study of Histotripsy Parameters for the Treatment of Fibrotic ex-vivo Human Benign Prostatic Hyperplasia Tissue.Res Sq [Preprint]. 2024 Jul 2:rs.3.rs-4549536. doi: 10.21203/rs.3.rs-4549536/v1. Res Sq. 2024. Update in: Sci Rep. 2024 Sep 2;14(1):20365. doi: 10.1038/s41598-024-71163-2. PMID: 39011101 Free PMC article. Updated. Preprint.
-
Incidence and Determinants of Catheter-Related Bladder Spasms Following Transurethral Resection of the Prostate; A Prospective Review of 80 Cases.Niger Med J. 2024 Apr 21;65(1):75-80. doi: 10.60787/nmj-v65i1-453. eCollection 2024 Jan-Feb. Niger Med J. 2024. PMID: 39006173 Free PMC article.
References
-
- Uptodate.com. Epidemiology and pathogenesis of benign prostatic hyperplasia, https://www.uptodate.com/contents/epidemiology-and-pathogenesis-of-benig... (accessed 10 July 2020).
-
- Litman HJ, Mckinlay JB. The future magnitude of urological symptoms in the USA: projections using the Boston area community health survey. BJU Int 2007; 100: 820–825. - PubMed
-
- Lee AJ, Garraway WM, Simpson RJ, et al. The natural history of untreated lower urinary tract symptoms in middle-aged and elderly men over a period of five years. Eur Urol 1998; 34: 325–332. - PubMed
-
- Duan Y, Grady JJ, Albertsen PC, et al. Tamsulosin and the risk of dementia in older men with benign prostatic hyperplasia. Pharmacoepidemiol Drug Saf 2018; 27: 340–348. - PubMed
-
- Tae BS, Jeon BJ, Choi H, et al. A-blocker and risk of dementia in patients with benign prostatic hyperplasia: a nationwide population based study using the national health insurance service database. J Urol 2019; 202: 362–368. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
